Mesangial proliferative glomerulonephritis pathophysiology

Mesangial proliferative glomerulonephritis Microchapters
Home
Overview
Pathophysiology
Causes
Differentiating Mesangial proliferative glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mesangial proliferative glomerulonephritis pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mesangial proliferative glomerulonephritis pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mesangial proliferative glomerulonephritis pathophysiology
CDC on Mesangial proliferative glomerulonephritis pathophysiology
Mesangial proliferative glomerulonephritis pathophysiology in the news
Blogs on Mesangial proliferative glomerulonephritis pathophysiology
Directions to Hospitals Treating Mesangial proliferative glomerulonephritis
Risk calculators and risk factors for Mesangial proliferative glomerulonephritis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pathophysiology

Mesangial cells in the renal glomerulus use endocytosis to take up and degrade circulating immunoglobulin. This normal process stimulates mesangial cell proliferation and matrix deposition. Therefore, during times of elevated circulating immunoglobulin (i.e. lupus and IgA nephropathy) one would expect to see an increased number of mesangial cells and matrix in the glomerulus. This is characteristic of nephritic syndromes.